Selurampanel (BGG 492) is a selective, orally active and competitive AMPA receptor (AMPAR) antagonist with IC50 of 0.19 uM.
Selurampanel (BGG 492) displays >100-fold selectivity over NMDA and kainate receptors.
Selurampanel (BGG 492) demonstrates excellent oral potency against MES-induced generalized tonic-clonic seizures in rodents as well as significant activity in patients suffering from various forms of epilepsy.
